Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HPV (human papillomavirus) levels could identify cervical cancer risk earlier

This article was originally published in Clinica

Executive Summary

Women at high risk of developing cervical cancer could be identified 10 years or more before the appearance of the disease by measuring the viral load of human papillomavirus type 16 (HPV 16), according to the findings of two multinational studies. Writing in the June 24 issue of The Lancet, researchers from Sweden, Denmark and the US suggest that measurement of viral load could usefully be added to routine gynaecology examinations such as Pap screening.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT076568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel